ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update

ProQR Therapeutics (NASDAQ:PRQR) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 918,100 shares, an increase of 151.7% from the December 15th total of 364,700 shares. Based on an average daily volume of 1,520,000 shares, the short-interest ratio is presently 0.6 days.

Analysts Set New Price Targets

PRQR has been the subject of a number of research analyst reports. Oppenheimer began coverage on ProQR Therapeutics in a research note on Friday. They issued an “outperform” rating and a $15.00 target price for the company. Chardan Capital reissued a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Finally, StockNews.com cut shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, ProQR Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PRQR. OneDigital Investment Advisors LLC boosted its holdings in shares of ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 15,550 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 7,300 shares during the period. Finally, Privium Fund Management B.V. increased its stake in shares of ProQR Therapeutics by 0.9% during the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock worth $10,251,000 after purchasing an additional 51,663 shares during the last quarter. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Price Performance

PRQR stock traded down $0.01 during midday trading on Tuesday, hitting $2.26. The company’s stock had a trading volume of 357,486 shares, compared to its average volume of 319,648. The company’s fifty day moving average price is $3.18 and its 200 day moving average price is $2.53. ProQR Therapeutics has a twelve month low of $1.61 and a twelve month high of $4.62. The stock has a market capitalization of $184.60 million, a P/E ratio of -7.06 and a beta of 0.30.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).